Overall market sentiment has been down on Mesoblast limited (MESO) stock lately. MESO receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With MESO Stock Today?
Mesoblast limited (MESO) stock has fallen -4.05% while the S&P 500 is up 0.4% as of 11:59 AM on Monday, May 3. MESO has fallen -$0.31 from the previous closing price of $7.66 on volume of 227,339 shares. Over the past year the S&P 500 has risen 47.67% while MESO has fallen -31.37%. MESO lost -$0.88 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Mesoblast limited click here.
More About Mesoblast limited
Mesoblast is a small cap biotech company with listings on both the ASX and the Nasdaq. The company has acquired the rights to develop and commercialize certain regenerative medicine technologies aimed at innovative ways of treating inflammatory diseases. Of their product pipeline, three product candidates are currently in phase three trials, with the first drug in the FDA approval application process and a possible U.S. launch date in early fiscal 2021. The company has sold the rights to develop and commercialize some of its technologies in Japan, Europe and China from which it earns milestone and ongoing licence revenues once the products are marketed. Mesoblast is currently in the R&D phase and is loss-making.
Click Here to get the full Stock Score Report on Mesoblast limited (MESO) Stock.
